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SHANK3 is located on chromosome 22q13.3 and encodes a scaffold protein that is found in excitatory
synapses opposite the pre-synaptic active zone. SHANK3 is a binding partner of neuroligins, some of whose
genes contain mutations in a small subset of individuals with autism. In individuals with autism spectrum
disorders (ASDs), several studies have found SHANK3 to be disrupted by deletions ranging from hundreds
of kilobases to megabases, suggesting that 1% of individuals with ASDs may have these chromosomal
aberrations. To further analyse the involvement of SHANK3 in ASD, we screened the International
Molecular Genetic Study of Autism Consortium (IMGSAC) multiplex family sample, 330 families, for SNP
association and copy number variants (CNVs) in SHANK3. A collection of 76 IMGSAC Italian probands from
singleton families was also examined by multiplex ligation-dependent probe amplification for CNVs. No
CNVs or SNP associations were found within the sample set, although sequencing of the gene was not
performed. Our data suggest that SHANK3 deletions may be limited to lower functioning individuals with
autism.
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Introduction
Autism is a severe neurodevelopmental disorder and one of
the most heritable neuropsychiatric syndromes, with a
male to female ratio of 4:1.1 The diagnosis of autism is
based on impairments in reciprocal social interaction and
communication, and restricted and stereotyped patterns
of interests and activities, with abnormal development
apparent within the first 3 years of life.2 Autistic spectrum
disorders (ASDs) include: autistic disorder, childhood
disintegrative disorder, pervasive developmental disorder-
not otherwise specified, Asperger syndrome and Rett
syndrome. The prevalence of childhood autism is
estimated at 38.9 per 10000 with the total prevalence for
all ASDs at 116.1 per 10 000.3
There is substantial evidence from twin and family
studies4–7 to support the involvement of genetic factors
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in ASDs. Statistical modelling of the pattern of inheritance
in the idiopathic form of the disorder implicates 3–15
genes, suggesting an oligogenic mode of inheritance.8,9
The contribution of chromosomal structural variation to
differences in genetic makeup within the human popula-
tion has recently been highlighted.10 Advances in techno-
logy have enabled the screening of large cohorts of
individuals for copy number variants (CNVs) genome-
wide. A number of such studies have been published,11–16
which have found that CNVs appear to have a larger causal
role within autism than previously thought.
Several CNVs have been found in SHANK3 (SH3 and
multiple ankyrin repeat domains protein 3, also known as
ProSAP2). SHANK3 belongs to the family of SHANK
proteins, which were first identified in the rat17 and
subsequently in humans.18 These proteins are believed to
function as molecular scaffolds in the post-synaptic density
(PSD)19 of excitatory synapses and aid in the assembly of
protein complexes within cells by containing multiple
binding domains for protein–protein interaction.20
SHANK3 is located on chromosome 22q13.3, spans
approximately 58Kb of genomic sequence, and contains
24 exons, 7 of which are alternatively spliced,21 which may
influence the spectrum of SHANK-interacting proteins at
the PSD. Its expression pattern in the brain is confined to
the cortex, hippocampus and cerebellum.20
SHANK3 was first implicated in the field of neuro-
psychiatric disorders when a patient with terminal
22q13.3 deletion syndrome was found to have a de novo
reciprocal translocation that disrupted the gene.18 22q13.3
deletion syndrome includes the phenotypes of severe
expressive language delay, severe/profound mental retarda-
tion and at times autism. Since the initial report, a number
of studies22–25 have described further cases of 22q13.3
deletion syndrome with disruption or deletion of SHANK3.
This finding has led to the hypothesis that haploinsuffi-
ciency of SHANK3 may cause the behavioural phenotypic
consequences of 22q13.3 deletion syndrome.
Owing to its emerging role in neuropsychiatric disorders
and the overlap of phenotypes between autism and
22q13.3 deletion syndrome SHANK3 was further analysed
in patients with ASDs. Durand et al21 found three separate
families containing disruptions or deletions of SHANK3
that were not identified in controls. Interestingly, each
individual with either a deletion of SHANK3 or a truncated
protein had severe language problems, whereas the
individual with 22qter partial trisomy had precocious
language development and fluent speech, but social
communication difficulties.21 Subsequent studies have
discovered de novo deletions and mutations of SHANK3
in individuals with autism, 11,13,26,27 adding support to the
role of the gene within the autistic phenotype.
Given the emerging evidence for SHANK3 haploinsuffi-
ciency in some individuals with autism, DNA samples from
319 multiplex families and 11 trios, from the International
Molecular Genetic Study of Autism Consortium (IMGSAC)
multiplex cohort, were analysed for CNVs and SNP
association across this locus. DNA samples from 76
IMGSAC probands with autism from Italian singleton
families were also investigated for CNVs.
Materials and methods
Subjects
Multiplex families were identified, collected and assessed
by IMGSAC as described earlier.28,29 In short, after passing
an initial screen, parents were administered the Autism
Diagnostic Interview-Revised (ADI-R)30 and the Vineland
Adaptive Behavior Scales.31 Probands were assessed using
the Autism Diagnostic Observation Schedule-Generic
(ADOS-G),32 and a medical examination was carried out
to exclude cases of known aetiology, for example tuberous
sclerosis. IQ was assessed using the Ravens Progressive
Matrices coloured33 or standard and the Picture Vocabulary
Test BPVS34 or PPVT.35 Karyotyping was performed when
possible on probands and molecular genetic testing for
Fragile X syndrome on one affected individual in each
family. Written informed consent was obtained from all
parents/guardians or, where appropriate, the proband. The
relevant ethical committees approved the study. A blood
sample was taken from all affected individuals and first-
degree relatives and a lymphoblastoid cell line created. If
blood was unavailable a buccal swab was taken instead.
DNA was extracted from blood, cell lines and buccal swabs
by means of a DNA purification kit (Nucleon BACC2 Blood
and Cell Culture DNA purification kit, Tepnel Life Sciences,
Manchester, UK). A total of 319 IMGSACmultiplex families
and 11 IMGSAC trios were genotyped, with a male/female
ratio of 4.3:1 in probands. Seventy-six IMGSAC Italian
probands from a singleton family collection, who all meet
IMGSAC criteria for inclusion, were also screened for distal
chromosome 22q CNVs by multiplex ligation-dependent
probe amplification (MLPA).
SNP genotyping
CEU genotypes for the region on chromosome 22q13.3
covering the SHANK3 gene, including 5kb of sequence
upstream (chromosome 22: 49 398 550–49 464 810bp,
NCBI Build 35), were downloaded from the HapMap phase
II (release 21). Fifteen haplotype-tagging SNPs were chosen
across SHANK3 using Tagger in Haploview v4.0beta1236
(aggressive tagging, r 2 4 0.8, MAF 4 0.05), that tagged in
total 23 SNPs (including themselves), of which 95.7% of
alleles were captured with an r 240.8. DNA was quantified
using the Picogreen dsDNA Quantitation Kit (Invitrogen).
A total of 40ng of genomic DNA was genotyped using the
Sequenom MassARRAY i-PLEX Gold assay (Sequenom, San
Diego, USA). Two control DNA samples were included on
each plate to check for inter-plate reproducibility. SNP
genotype calls were verified visually using the Sequenom
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MassARRAY Typer software (version 3.1.4.0). Merlin error
checks37 were performed to identify unlikely genotypes
within the data set and Pedwipe used to remove them
from the pedigree file. Genotypes were uploaded to the
Integrated Genotyping System.38
Statistical analysis of SHANK3 genotypes
Hardy–Weinberg equilibrium was verified for the SNPs
genotyped, in all individuals and in unrelated individuals,
using PEDSTATS.39 All families were checked for Mendelian
inconsistencies by PedCheck40 and two subsequently
removed because of bad inheritance found in the SHANK3
SNPs and those of another gene genotyped simultaneously,
thus reducing the likelihood of detection of de novo
deletions. Association analysis was carried out on the
IMGSAC Caucasian families. STATA (StataCorp: Stata
Statistical Software Release 7.0, Stata Corporation: College
Station, TX, USA) was used to perform single locus
transmission disequlibrium test (TDT)41 association analy-
sis, taking into account pedigrees, and case/pseudo–
control analysis42 that uses untransmitted genotypes as
pseudocontrols. Genotypes were constructed for three
‘pseudo–controls’, which consist of the other possible
genotypes that the offspring could have received from their
heterozygous parents. Two haplotype-tagging SNPs to-
gether tested another SNP and so TDT was also performed
for this haplotype within Haploview.
Fluorescence in situ hybridisation
The extent of SNP homozygosity across SHANK3 was
examined as a potential indicator of hemizygosity. Overall,
53 individuals (23 affected individuals, 25 parents and 5
unaffected siblings) were selected for analysis by FISH
(fluorescent in situ hybridisation), as they were homo-
zygous for all 14 haplotype-tagging SNPs successfully geno-
typed. One individual who was homozygous at only two
SNPs was used as a control. Chromosome preparations for
FISH analysis were obtained from the EBV-transformed
lymphoblastoid cell lines following standard techniques.
Two fosmid probes kindly provided by Dr. Stephen Scherer,
G248P86064C8 and G248P86149G7, were labelled with
Digoxigenin-11-dUTP (Roche) by nick-translation (Vysis kit)
and separately co-hybridised with an FITC-labelled ‘paint’ for
chromosome 22 (Cambio), following standard procedures.
The fosmid probe signals were detected with Rhodamin anti-
Digoxigenin (Roche), and the chromosomes were counter-
stained with DAPI in Vectashield (Vector Laboratories). The
slides were examined using an Olympus BX-51 epifluores-
cence microscope coupled to a Sensys charge-coupled device
camera (Photometrics). At least 20 informative cells were
analysed for each hybridisation experiment.
MLPA
Mulitplex ligation-dependent probe amplification reac-
tions using probe mix SALSA P188 MLPA KIT 22q13 Lot
0407, 0906 were performed on 100ng genomic DNA
from 94 IMGSAC multiplex affected individuals, 76 Italian
singleton affected individuals and one positive control
individual harbouring a known SHANK3 deletion24
of 100 kb (DNA kindly provided by Dr. Maria Clara
Bonaglia). The P188 kit and protocol43 were supplied by
MRC-Holland (Amsterdam, The Netherlands). PCR
products were separated on a 96-capillary Applied
Biosystems 3700 DNA Analyzer. Peak size was verified using
Genotyper 2.0 (Applied Biosystems, Foster City, USA).
Coffalyser software v844 was used to analyse the
MLPA data for CNVs. Bin sizes were adjusted accordingly
for the peak sizes observed. Data were normalised
by division of each probe’s peak area by the average peak
area of the seven control probes in the probe mix obtained
from the sample set. The normalised data were then
divided by the median peak area of all samples to obtain
an indication of copy number variation for each probe.
A figure of 0.7 or below and 1.3 and above were set
as thresholds for losses and gains, respectively. Two
consecutive probe deletions or duplications were necessary
for further investigation.
The affected IMGSAC individuals were chosen for
analysis through MLPA by identifying runs of consecutive
homozygosity in the 14 successfully genotyped haplotype-
tagging SNPs. All affected individuals were ranked accord-
ing to the number of consecutive homozygous calls and
the 94 individuals with the largest number selected. This
sample included 18 individuals also tested by FISH and 76
others who contained between 8 and 14 homozygous calls.
Only one affected individual per multiplex family was
chosen; preferentially IMGSAC Case Type One (clinical
diagnosis of autism, meets ADI-R and ADOS or ADOS-G
criteria for autism, history of language delay, and perfor-
mance IQ of 435).29 The affected individuals in total
comprised 51 Case Type One, 30 Case Type Two, 2 Case
Type Three and 11 Case Type Four (See Supplementary
Table 1 for Case Type description). Among the affected
Italian individuals, 80% were either Case Type One or Two.
Overall, the probands selected were of a high functioning
nature and met strict criteria for autism.
Results
SNP genotyping
Fourteen haplotype tagging SNPs were successfully geno-
typed on the Sequenom system, all of which conformed to
Hardy–Weinberg equilibrium (P40.001). As only 14 of the
15 selected haplotype-tagging SNPs were successfully
genotyped, there was a reduction in tagging efficiency,
with 91.3% of alleles being captured with an r 240.8 rather
than 95.7%. Sample and SNP genotyping success rates were
99 and 93%, respectively, and inter-plate reproducibility
99.5%.
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Association analysis of SHANK3 SNPs
Family-based association analysis was carried out using the
STATA package on a subset of the samples genotyped,
comprised of Caucasian individuals, which included 297
IMGSAC multiplex families and 11 IMGSAC trios. Single
SNP TDT and a case/pseudo–control approach were
performed and no association was found (Table 1).
Copy number analysis by FISH mapping
Fluorescent in situ hybridisation was used to test for
chromosome rearrangements in individuals identified by
the SNP genotyping as displaying potential hemizygosity
in SHANK3. Out of the 53 individuals, 44 respective
lymphoblastoid cell lines were tested, consisting of 21
affected individuals (16 male and 5 female), 12 fathers, 6
mothers and 5 unaffected siblings. Eight individuals did
not have a cell line available and one cell line failed to
grow. A sample that was heterozygous at 12 out of 14 SNPs
in SHANK3 was also probed as a negative control.
Two fosmid clones, G248P86064C8 and G248P86149G7,
were used as FISH probes across a region ofB64kb covering
the SHANK3 gene to search for deletions in the selected
IMGSAC samples. Of the 45 lymphoblastoid cell lines
probed, including the control, no deletions were identified.
MLPA analysis
Multiplex ligation-dependent probe amplification was
used as a second method to look for smaller deletions
across SHANK3 not detectable by FISH. The 37 probes
within the P188 probe set cover a larger distance than the
fosmids, approximately 19Mb, enabling characterisation
of potential deletions. MLPA is also a higher throughput
technique than FISH; therefore, a greater number of
individuals could be analysed simultaneously.
Ninety-four affected individuals from IMGSAC multiplex
families, seventy-six affected individuals from IMGSAC
Italian singleton families and one positive control were
analysed using MLPA (Figure 1). Two individuals were
removed as they had SDs for the copy number ratios above
0.25, which was used as the cutoff for this sample. All probes
performed accurately apart from two within the geneMLC1,
MLC1 Probe 6335-L5910 and MLC1 Probe 6338-L5913,
which have been removed from Figure 1. No individual had
two or more consecutive probes showing deletions or
duplications within SHANK3, apart from the positive
control, which showed all seven probes deleted from exon
9 in SHANK3 to the telomere. Three affected individuals
exhibited two probes duplicated consecutively and one
affected individual had two probes deleted; however, these
events were all more than 150kb proximal to SHANK3.
Discussion
The IMGSAC multiplex family collection was analysed for
association and CNVs within SHANK3, using SNP geno-
typing, FISH and MLPA analysis. The SNP, fosmid and MLPA
probe positions are shown in Figure 2, comprehensively
covering the gene SHANK3. A smaller group of affected
individuals from an Italian cohort of IMGSAC singleton
families was also analysed by MLPA for CNVs in SHANK3.
The association analysis results from the SNP genotyping
in the IMGSAC families presented here were all nonsigni-
ficant. Nevertheless, no previous reports of association
with SHANK3 have been published, and one would not
expect to observe association of a rare deletion, if only
Table 1 Results of single SNP TDT and case/pseudo–control analysis in Caucasian families for the 14 haplotype-tagging
SNPs genotyped across SHANK3
Single SNP TDT Case/pseudo control analysis
Tagging SNP SNPs capured Global w2 (1 d.f.) P-value OR for allele 2 vs 1 95% CI P-value
rs9616915 rs9616915, rs9616913, rs9628185 0.04 0.84 1.02 (0.85–1.22) 0.84
rs2341009 rs2341009 1.44 0.23 1.14 (0.92–1.41) 0.23
rs2341010 rs1001469, rs2341010 0.41 0.52 1.08 (0.86–1.35) 0.53
rs2341011 rs736334, rs2341011, rs9616816 1.81 0.18 0.86 (0.69–1.07) 0.18
rs739365 rs739365 1.11 0.29 0.90 (0.75–1.09) 0.29
rs5770992 rs5770992 1.81 0.18 0.79 (0.57–1.11) 0.18
rs6010060 rs6010060 0.39 0.53 0.89 (0.63–1.27) 0.54
rs2040487 rs2040487 1.35 0.28 0.90 (0.75–1.09) 0.28
rs6010061 rs6009951, rs6010061 1.35 0.25 0.90 (0.75–1.07) 0.25
rs2106111 rs2106111 0.27 0.60 0.95 (0.80–1.14) 0.60
rs6010063 rs6010063, rs6010065 0.47 0.49 1.06 (0.89–1.27) 0.49
rs715586 rs715586 0.03 0.87 0.98 (0.76–1.26) 0.87
rs8137951 rs8137951 0.48 0.49 0.93 (0.76–1.14) 0.49
rs756638 rs756638 0.22 0.64 1.05 (0.86–1.28) 0.64
rs739365,
rs6010061
rs5770820 0.48 0.49
CI, confidence interval; df, degrees of freedom; OR, odds ratio.
The SNPs captured by the tagging SNPs are also shown.
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present in a small number of individuals. Sequence
analysis was not conducted, and so rare mutations
potentially could have been missed within SHANK3, such
as those found in previous studies.21,26,27 The sample size
of the IMGSAC cohort of families is relatively small in
comparison with larger genome-wide association and CNV
detection studies that are currently being carried out,12,16
and so this must also be taken in to consideration.
The SNP genotyping was used as a crude indication of
potential hemizygosity across SHANK3 within the IMGSAC
multiplex families. Unfortunately, the Sequenom system
was unable to provide quantitative information about
signal intensity from the genotype calls, and so the
distinction between a true homozygous call and a hemi-
zygous call could not be distinguished by simple analysis of
an output file. Therefore, those individuals homozygous
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Figure 1 Copy number analysis using MLPA on the region chr22q12.2-q13.33 in 168 autistic probands from IMGSAC multiplex families and Italian
singleton families. The thresholds for gains and losses are marked as 1.3 and 0.7, respectively. The positive control sample clearly shows the loss of
SHANK3, ACR and RABL2B. Graph not to scale. For a complete list of the probes and their positions see MRC-Holland probe mix P188 lot 0407, 0906.
Figure 2 Positions of SNPs, fosmids and MLPA probes within SHANK3 (UCSC May 2004, NCBI Build 35). Exons annotated as those in the study by
Durand et al.21
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for all haplotype-tagging SNPs across the region were
probed using FISH.
The two probes used for FISH are each approximately
40 kb in length, and so if the deletion occurred within the
probe sequence, but still allowed the probe to hybridise, a
fluorescent signal would still be seen and a deletion missed.
To overcome this problem, MLPA was used to potentially
identify smaller aberrations. This technique relies on
hybridisation of probes on either side of a target sequence
and subsequent ligation that permits amplification. The
amount of PCR product, dependent on ligation, indicates
copy number. No CNVs within SHANK3 were identified by
this technique. This finding could have been due to the
method of selection of the affected individuals tested; 94
individuals with the most consecutive homozyogous SNPs.
Individuals with just a few homozygous calls at either end
of SHANK3 were not included in the analysis, but could be
representative of a deletion extending outwards from the
extremities of the gene. This method of choosing affected
individuals preferentially selected for deletions and so
duplications may have been missed, whereas the Italian
singleton sample was not preselected, hence equally likely
to harbour deletions or duplications. Four affected indivi-
duals did demonstrate events of two consecutive probes
duplicated or deleted, positioned at greater than 150 kb
proximal to SHANK3, these regions were deemed not to be
directly affecting the expression of the SHANK3 gene
when interrogated by the use of an expression database
(mRNA_bySNP_browser_v1.0.1.exe45).
The majority of IMGSAC families analysed were multi-
plex in origin. Recent reports have suggested that the
prevalence of de novo CNVs in singleton families is between
7 and 10%, whereas in multiplex families it is 2–3%.11,13
As the majority of SHANK3 CNVs identified are de novo in
origin, this would decrease the probability of detecting an
event within our multiplex family sample set, particularly
as no Mendelian errors were found during the SNP
genotyping. Although the Italian individuals that were
tested by MLPA originated from singleton families, no
CNVs were identified within these affected individuals.
Another reason for the lack of CNVs identified within
this study could be because of the inclusion criteria used to
select IMGSAC multiplex and singleton families. The
majority of affected individuals are higher functioning
and meet a more narrowly defined diagnosis of autism
than those that have been reported with SHANK3 CNVs in
previous papers.21,26 Seventy six percent of the IMGSAC
affected individuals assessed by MLPA had performance IQ
data available with a mean of 78 (SD¼30), whereas severe
mental retardation was described for some autistic indivi-
duals with SHANK3 aberrations by Durand et al.21
SHANK3 is a binding partner of the neuroligins,46 which
in turn have ligands in the form of the neurexins. Both of
these protein families contain genes within which rare
mutations have been identified in autism; NLGN347,48 and
NLGN4,47–49 CNTNAP250 and NRXN1.12,51 Nevertheless,
coding mutations in NLGN3 and NLGN4 have not been
found to be associated with autism in IMGSAC families,52
and no CNVs have been identified in SHANK3 using the
methodology described here, although sequence analysis
may have detected rare variants. Despite this negative
finding, a number of genes within the synaptic network
could still be harbouring mutations, which could lead to a
similar phenotypic end point. Further analysis of these
genes for CNVs within the IMGSAC cohort is warranted.
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